摘要
目的评价胰激肽原酶治疗糖尿病视网膜病变疗效。方法检索关于胰激肽原酶治疗糖尿病视网膜病的随机对照试验(RCTs),检索系统包括中国知网数据库、万方数据库、Pub Med、Cochrane Database of Systematic Reviews、EMbase等,筛选最近10年的相关文献。将符合标准的初选文献汇总,并对文献中的方法学进行评价。在初选文献基础上进行文献质量评价,并对最终纳入的文献并进行资料提取,随后通过Review manager 5.3软件对数据进行Meta分析。结果 6个RCTs共866例患者纳入研究,其中治疗组(胰激肽原酶)448例,对照组(常规药物治疗)418例。Meta分析结果表明,胰激肽原酶在治疗糖尿病视网膜病变总有效率明显高于一般治疗药物,差异有统计学意义(OR=2.73,95%CI:1.89~3.95)。结论胰激肽原酶治疗糖尿病视网膜病变总有效率高于常规药物治疗治疗。本研究不足之处是所选样本数量较小,样本质量级别中等,对于本研究获得结论尚需通过更多试验进行验证。
Objective To investigate the treatment efficiency of pancreatic kininogenase on the diabetic retinopathy. Methods Lit- erature research was performed to select the randomly controlled trials （RCTs） about the related studies in the PubMed, Cochrane Data- base of Systemic Reviews, EMbase, CNKI, and Wanfang database. Besides, the references were also screened, and the methodology was evaluated. The quality of the reference was strictly evaluated, and Meta analysis was carried out using Review Manager 5.3 software for the qualified RCTs. Results A total of 866 patients from 6 RCTs were included in this study, including 448 patients received pancreatic kininogenase and 418 patients received control group. The results revealed pancreatic kininogenase was superior to the conventional drug treatment （ OR = 2.73,95% CI： 1.89 - 3.95 ）. Conclusion Pancreatic kininogenase was superior to the conventional drug treatment for the treatment of diabetic retinopathy. In future studies, more high - quality RCTs are needed to confirm this conclusion.
出处
《医学研究杂志》
2017年第1期160-163,共4页
Journal of Medical Research
关键词
胰激肽原酶
糖尿病视网膜病
疗效
META分析
Pancreatic kininogenase
Diabetic retinopathy
Treatment efficiency
Meta analysis
